Humoral immunity depends on efficient activation of B cells and their subsequent differentiation into antibody-secreting cells (ASCs). The transcription factor NFkB cRel is critical for B cell proliferation, but incorporating its known regulatory interactions into a mathematical model of the ASC differentiation circuit prevented ASC generation in simulations. Indeed, experimental ectopic cRel expression blocked ASC differentiation by inhibiting the transcription factor Blimp1, and in wild-type (WT) cells cRel was dynamically repressed during ASC differentiation by Blimp1 binding the Rel locus. Including this bi-stable circuit of mutual cRel-Blimp1 antagonism into a multi-scale model revealed that dynamic repression of cRel controls the switch from B cell proliferation to ASC generation phases and hence the respective cell population dynamics. Our studies provide a mechanistic explanation of how dysregulation of this bi-stable circuit might result in pathologic B cell population phenotypes and thus offer new avenues for diagnostic stratification and treatment.
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In Brief Antibody production requires proper phasing of B cell proliferation and differentiation. Using an iterative systems biology approach, Roy et al. reveal that, although NFkB cRel enables proliferation, it must be downregulated during differentiation. Multi-scale modeling shows how coordinated cRel and RelA dynamics control B cell populations in health and disease.
INTRODUCTION
The production of antibodies is key for an effective immune response and efficacy of vaccination. Recognition of foreign antigens leads to profound changes within secondary lymphoid organs, including the formation of the germinal center (GC) and extrafollicular foci that allow for the rapid expansion of antigenspecific B cell clones to produce neutralizing antibodies and memory B cells. Indeed, T-cell-independent (TI) and T-celldependent (TD) stimulation of B cells generates rapidly proliferating cells known as activated B cells (ABCs). ABCs can differentiate into actively cycling short-lived plasmablasts (PBs), which develop in the early phases of an immune response, and quiescent long-lived plasma cells (PCs), which reside in a specialized bone marrow niche. Given that both PBs and PCs are capable of producing antibodies, they are referred to as antibody-secreting cells (ASCs) (Shapiro-Shelef and Calame, 2005) . The transition of ABCs to ASCs is coordinated by changes in signaling, gene expression, and chromatin regulatory networks. ABC-specific transcription factors (such as Pax5 and Bach2) and ASC-specific transcription factors (such as Blimp1) regulate distinct genetic programs (Kallies et al., 2007; Nutt et al., 2015) . Misregulation of these mutually inhibiting transcription factors, caused by common mutations, can result in B cell lymphomas with poor prognosis (Mandelbaum et al., 2010; Nutt et al., 2015; Xia et al., 2017) . Transcription factor NFkB is also dysregulated in many B cell lymphomas (Shaffer et al., 2002b) , and its inhibition is lethal to these transformed cells (Ceribelli et al., 2014; Staudt, 2010) .
NFkB is a key inflammatory and immune transcription factor consisting of a dozen dimers made up of three activation domain-containing proteins (cRel, RelA, and RelB) and two dimerization partners (p50 and p52) (Hoffmann and Baltimore 2006) . In ABCs, the NFkB dimers RelA:p50 and cRel:p50 are induced (Kaileh and Sen, 2012) . Whereas cRel activity is required for cell survival, growth, and division during B cell activation (Pohl et al., 2002; Shokhirev et al., 2015) , RelA is required for the generation of GC-derived PCs by contributing to Blimp1 activation (Heise et al., 2014) . Thus, both cRel and RelA are indispensable for humoral immunity but for different functional reasons. However, a recent study showed that in the genetic disease B cell expansion with NFkB and T cell anergy (BENTA), constitutively active NFkB results in reduced ASC generation (Arjunaraja et al., 2017) , suggesting that precise regulation of each NFkB dimer is required for healthy ASC generation.
Mathematical modeling approaches have proven valuable to understanding complex dynamic molecular regulatory networks. ABC population expansion dynamics are well accounted for by a multi-scale model of the intracellular molecular network of NFkB regulating apoptosis and the cell cycle (Mitchell et al., 2018; Shokhirev et al., 2015) , and this model proved useful in understanding the function of cRel in cell survival, growth, and division (Shokhirev et al., 2015) . In the case of the ASC differentiation circuit, the scarcity of quantitative biochemical data first prompted logical models that can qualitatively recapitulate the state of regulatory networks in the terminal fates of B cells (Mé ndez and Mendoza, 2016) or a dynamical system of only three regulators (Martínez et al., 2012) . Larger dynamical models are capable of explaining the distribution of time spans that B cells can spend undergoing somatic hypermutation (SHM) prior to terminal differentiation but either do not include NFkB, cRel, or RelA (Sciammas et al., 2011) or consider NFkB as a single regulator without distinct functions of cRel or RelA (Martínez et al., 2012; Mé ndez and Mendoza, 2016) .
To better understand the role of NFkB within the ASC differentiation circuit, we extended the work of Sciammas et al. (2011) by developing a mathematical model of ASC differentiation in which cRel and RelA are investigated as distinct regulators. Mathematical modeling, combined with mechanistic and functional experimental studies, revealed that cRel must be repressed for ASC differentiation. We showed that decreased cRel expression is mediated by Blimp1 through epigenetic remodeling of the Rel locus. This insight allowed us to integrate the extended ASC differentiation circuit model into our previously established multi-scale model to account for the cell population dynamics of ABCs and ASCs in terms of the dynamics of intra-cellular molecular signaling events.
RESULTS

Mathematical Modeling Predicts that cRel Inhibits B Cell Differentiation into ASCs
The previously established ASC differentiation circuit model (Sciammas et al., 2011) includes regulatory interactions between transcription factors IRF4, Pax5, Blimp1, Bach2, and Bcl6 (Figures 1A and 1B) . To explore the roles of NFkB dimers in ASC differentiation, we incorporated RelA and cRel and their known dimer-specific regulatory interactions into the ordinary (Sciammas et al., 2011) . (D) Kinetics of ASC differentiation predicted by Sciammas et al. (2011) . Shown are the ASC differentiation model and the NFkB-extended ASC differentiation model v1. The percentage of ASCs is plotted with time (h). The solid line indicates the mean, and the shaded region indicates the standard deviation of 3 simulations of 125 cells.
(E) The final states (96 h) reached by cells expressing high Blimp1 in simulations of 125 starting cells with the NFkB-extended ASC differentiation model v1 (phase 1, green) and a subsequent simulation in which cRel activity in those cells was reduced to 1% and trajectories were simulated for 96 h (phase 2, red).
(F) Bar graph of the fraction of ABCs becoming ASCs when cRel was allowed to remain at 100% of its expression (phase 1, green) or when it was forcibly reduced to 1% of its peak (phase 2, red). Median (black), standard deviation (SD; dark green), and standard error of the mean (SEM; light green) are indicated.
differential equation (ODE) model of Sciammas et al. (2011) : cRel is known to induce IRF4 (Grumont and Gerondakis, 2000) , Bach2 (Hunter et al., 2016) and activation-induced deaminase (AID) activity (Kim and Tian, 2009; Park et al., 2009) ; and RelA induces IRF4 (Saito et al., 2007) , Blimp1 (Heise et al., 2014; Morgan et al., 2009 ) and AID (Park et al., 2009 ) ( Figure 1B and Table S1 ). The resulting ''NFkB-extended ASC model v1'' contains 7 molecular species controlled by 14 regulatory interactions ( Figure 1B , Table S2 , and Data S1). Time-course simulations showed that ASC differentiation trajectories passed through an obligate transient state of high AID followed by increased Blimp1 and subsequent AID repression to become ASCs ( Figure 1C ). To interpret model simulations, we defined an ASC as a cell that is Blimp1 high and AID low (Blimp1 > 4, consistent with Sciammas et al., 2011, and AID < 4) ( Figure S1A ). However, simulations using the NFkBextended ASC model v1 failed to produce ASCs in expected numbers ( Figures 1C and 1D ). AID and Blimp1 upregulation were consistent with published results, but increased Blimp1 expression was not followed by the obligate AID decrease (Figures 1C and 1D) . At face value, this simulation result suggests that either RelA or cRel acts as an inhibitor of ASC differentiation. Given that RelA is required for ASC generation (Heise et al., 2014) , we wondered whether decreased cRel expression would allow ABCs that had failed to repress AID to complete their differentiation and become ASCs ( Figure 1E ). We simulated the effect of decreasing cRel expression (100-, 10-, or 5-fold) in cells that had elevated Blimp1; the model predicted that decreased cRel expression allows for substantial downregulation of AID (Figures 1E, S1B, and S1C), enabling the differentiation of ABCs to ASCs ( Figure 1F ). This effect was independent of the thresholds chosen to define an ASC ( Figure S1A ). Thus, math modeling suggested (1) that cRel might be repressed during ASC differentiation and (2) that this regulatory feature might be necessary for ASC generation.
Transcriptional Repression of Rel in ASCs
To test the first model prediction, we generated ABCs and ASCs ex vivo by stimulating mature B cells with the TI stimulus lipopolysaccharide (LPS) ( Figure S2A ) (Kallies et al., 2007) . The resulting ASCs showed increased expression of Blimp1 and IRF4 and decreased Bach2 expression compared with expression in ABCs (Figure 2A ), confirming that LPS-generated ASCs (defined here as LPS-PBs) can recapitulate key regulatory events of in vivo ASCs Nutt et al., 2015; Shapiro-Shelef and Calame, 2005; Shi et al., 2015; Tarlinton et al., 2008) . We examined cRel expression by immunoblotting and found that, although both cRel and RelA expression increased during B cell activation, cRel expression decreased $3.5-fold in LPSPBs, whereas RelA remained high (Figures 2A and 2B ). The same results were observed when PBs were generated with the TD stimulus anti-CD40 and IL-4 (defined as CD40-PBs) (Figures S2B-S2D) (Kallies et al., 2007) . By analyzing deposited RNA-sequencing (RNA-seq) data (Shi et al., 2015) , we found that Rel mRNA was lower in splenic PBs than in GC B cells and still lower in splenic PCs and bone marrow PCs ( Figure S2E ). By measuring mRNA with quantitative RT-PCR, we found that Rel expression was decreased $3-fold in LPS-PBs, whereas Rela expression remained similar ( Figure 2C ), and that Blimp1 and IRF4 expression was increased, whereas Bach2 expression was decreased ( Figure S2H ). This indicated that cRel repression occurred at the transcriptional level. To validate these observations in vivo, we generated ASCs and GC B cells by using immunization with TD antigen (NP-OVA). We purified lymph nodederived ASCs (LN-ASCs) and GC B cells by using flow-cytometry sorting ( Figures S2F and S2G ). We found that Rel transcripts were decreased $20-fold in LN-ASCs compared with GC B cells, whereas Rela remained similar ( Figure 2D ), and that Blimp1 and IRF4 were increased, whereas Bach2 was decreased (Figure S2I ). We also found that cRel expression was decreased in intestinal ASCs (I-ASCs), and these cells showed elevated Blimp1 compared with that in other B cells ( Figures S2J and S2K ). Altogether, these data suggest that decreased cRel expression could be a general characteristic of PBs and PCs irrespectively of the nature of stimulation and tissue environment.
Repression of Rel Is Required for ASC Differentiation
To test the second model prediction that Rel repression is functionally required for ASC differentiation, we used the BCL1 cell line, which is capable of stimulus-responsive differentiation into ASCs, as evident by gene expression signature (Sciammas and Davis, 2004) and antibody production (Lin et al., 1997; Sciammas and Davis, 2004) . We found that BCL1 cells stimulated with IL-2 and IL-5 recapitulated the Rel repression ( Figures  S2L and S2M ) observed in primary B cells (Figures 2 and S3 ). We ectopically expressed cRel in BCL1 cells (BCL1-cRel), which elevated Bach2 and diminished Blimp1 proteins ( Figure S2M ) and increased the proportion of cells in cell cycle ( Figure S2N ). Similarly, Bach2 transcript was increased ($2.5-fold) and Blimp1 transcript was diminished ($1.6-fold) ( Figures 2E and 2F ), indicating transcriptional control. However, ectopic expression of cRel also diminished the increase in Blimp1 after stimulation ($1.7-fold, compared with $3-fold in controls) ( Figure 2F ). We also found that BCL1-cRel cells failed to produce immunoglobulin M (IgM) upon stimulation ( Figure 2G ) and did not show a substantial reduction in the proportion of actively cycling cells ($32% compared with $35% in unstimulated cells) ( Figure S2N ). Thus, ectopic expression of cRel appears to block terminal differentiation of B cells.
It has been shown that Bach2 À/À B cells have higher Blimp1
and a higher propensity to differentiate into ASCs than WT controls (Muto et al., 2010) . We wondered whether the failure to increase Blimp1 expression in BCL1-cRel cells is mediated by Bach2. We deleted Bach2 in BCL1-cRel cells ( Figure S2O ) by using CRISPR/Cas9, which reverted Blimp1 expression to the same level as in control BCL1 cells ( Figure 2H ) and allowed for differentiation to ASCs, as evident by a rescue of IgM production ( Figure 2I ). We concluded that for ASC differentiation to proceed, Rel must be repressed for expression of Bach2 to decay and thus for Blimp1 to be de-repressed.
Blimp1 Mediates Transcriptional Repression of Rel
Given that our computational and experimental studies indicated that decreased cRel expression is required for ASC production, we wondered whether Blimp1 might transcriptionally repress Rel. In ''NFkB-extended ASC model v2'' ( Figure 3A) , we tested whether an inhibitory connection between Blimp1 and cRel production was sufficient to account for ASC generation quantitatively. Indeed, the model recapitulated experimental flow-cytometry results ( Figures 3B and 3C ) within a broad range of Blimp1 and AID thresholds used to define ASCs ( Figure S3 ). Thus, the mathematical model predicted that Blimp1-mediated repression of Rel might be sufficient to allow ASC differentiation. To experimentally test whether Blimp1 triggers repression of Rel, we deleted Blimp1 in BCL1 cells ( Figure S4A ) and measured Rel transcripts upon stimulation. Whereas control BCL1 cells showed a $4-fold decrease in Rel expression in response to stimulation with IL-2 and IL-5, Blimp1-deleted BCL1 cells failed to repress Rel upon stimulation ( Figure 4A ), and Rela expression remained largely unchanged ( Figure 4B ). Blimp1-deleted BCL1 cells were unable to proceed with ASC differentiation, as evident by the lack of IgM production ( Figure 4C ). Further, by analyzing RNA-seq data of primary B cells (Tellier et al., 2016) To establish whether Blimp1-mediated transcriptional repression of Rel is direct, we examined recently deposited Blimp1 ChIP-seq data from PBs and found a prominent Blimp1 binding peak in the Rel locus at position $23,669,376-23,670,485 in chromosome 11 by using genome assembly mouse mm9 ( Figure 4D ). Whereas BCL1 cells showed a $4-fold transcriptional repression of Rel in response to stimuli, CRISPR/Cas9-mediated disruption of a Blimp1 binding site in the Rel locus (Rel BBS ; Figure S4C ) substantially reduced this repression ( Figure 4E ). Rela expression remained unchanged in either cell line ( Figure 4F ). As expected, the Rel BBS mutation rendered BCL1 cells unable to fully proceed with ASC differentiation, as made evident by reduced IgM production ( Figure 4G ). Thus, we concluded that Blimp1 directly represses Rel expression in ASCs.
Next, we sought to characterize the mechanism by which Blimp1 represses Rel transcription. Blimp1 is known to interact with histone deacetylases (e.g., HDAC2) and was shown to repress transcription by recruiting HDACs to a target promoter (Yu et al., 2000) , reducing H3K9 acetylation (H3K9ac) abundance . We measured H3K9ac abundance on the Rel locus in ABCs and LPS-PBs by ChIP-qPCR and found a $1.4% ± 0.108% yield in ABCs as opposed to $0.4% ± 0.026% yield (relative to input) in LPS-PBs, whereas antibody isotype controls were low ($0.05%) and unchanged ( Figure S4D ). This reduction in H3K9ac by more than 3-fold on the Rel locus as ABCs differentiated into LPS-PBs contrasted with unchanged H3K9ac at $1.9% ± 0.1% on the Rela locus ( Figure S4E ). Similarly, ChIP-seq data showed reduced H3K9ac at the Rel locus ( Figure S4F ). Upon stimulation of BCL1 cells with IL-2 and IL-5, we found a $2.6-fold decrease in H3K9ac on the Rel locus in control cells (from $1.7% ± 0.19% to 0.64% ± 0.1%) but no significant change in Blimp1 À/À cells (from $1.84% ± 0.19% to 1.8% ± 0.2%) ( Figure 4H ). Similarly, mutation of the Blimp1 binding site (Rel BBS ) substantially diminished the loss of H3K9ac abundance in response to stimulus ($1.45% ± 0.11%) at the Rel locus compared with that in controls (0.64% ± 0.1%) ( Figure 4H ) but had no impact at the Rela locus ( Figure 4I ). Thus, we concluded that the differentiation-associated reduction of H3K9ac abundance at the Rel locus is dependent on direct binding of Blimp1 and leads to transcriptional repression of Rel in ASCs.
cRel Deficiency Increases the ASC Differentiation Propensity but Results in a Smaller ASC Population
To further test the regulatory mechanisms encapsulated in the computational model, we simulated ASC generation in the absence of cRel and found that the model predicted an increase in ASC numbers at time points after 48 h ( Figure 5A ). This prediction was independent of the threshold of Blimp1 and AID chosen to define a cell as an ASC ( Figure S5A ) and consistent with a previous report that Rel À/À B cells produce a higher percentage of ASCs after 3 days than WT controls (Heise et al., 2014) . In our experiments, we found that although Rel À/À B cells had a substantial proliferative defect and thus generated fewer cells overall than did WT cells ( Figure 5B ), the culture contained À1%, À2%, +20%, and +15% greater proportion of LPS-PBs than WT controls at 24, 48, 72, and 96 h, respectively (Figures 5C and S5B) . By measuring the cell loss associated with cRel deficiency, we found that the increased loss in the ABC population from 48 to 72 h (88% to 97%) coincided with a decreased loss of LPS-PBs from 48 to 72 h (91% to 86%) ( Figure S5C ). We also measured cell-death propensities with annexin V staining and found that ABCs and LPS-PBs generated from Rel À/À B cells showed a similar $2-fold higher rate of cell death than did those generated from WT B cells ( Figures S5D and S5E ). These data suggest that the increased proportion of LPS-PBs versus ABCs in Rel À/À B cells is not due to differential death rates, but rather due to an increased propensity to differentiate from ABCs into ASCs. These results show a quantitative agreement with computational predictions ( Figure 5A ), except for the last time point, which could reflect a limitation of the in vitro culture conditions. To further test the regulatory connections in the model, we generated quantitative predictions of the dynamic changes of three critical regulators (Blimp1, Bach2, and IRF4) after stimulation of Rel À/À versus WT B cells. In the mutant, we predicted a 2-fold late-phase increase in Blimp1, a 2-to 3-fold reduction in Bach2, and an initial decrease in IRF4 followed by a late-phase increase ( Figure 5D ). Experimental quantification by RT-PCR showed a quantitative match to the computational prediction such that Rel À/À B cells, compared with WT controls, had 2-fold higher expression of Blimp1 in the late-phase, 2-to 3-fold lower expression of Bach2, and similarly dynamic regulation of IRF4 (Figures 5E and S5F) . Immunoblots showed similar trends as observed by RT-PCR ( Figure 5F ). Thus, Rel À/À B cells had a higher propensity to differentiate into ASCs through increased expression of Blimp1 than did WT B cells. Given that ASC generation propensity has been shown to increase with cell division (Hasbold et al., 2004) our mechanistic understanding was sufficient to explain the effects we observed on differentiation and proliferation and the link between the two. This multi-scale model includes an NFkB module that predicts NFkB-dimer-specific dynamics as a result of the stimulus-induced regulation of multiple inhibitors of NFkB (IkBs). We added NFkB's control over ASC differentiation, as described here in ''NFkB-extended ASC model v2,'' to existing NFkB-mediated control over the cell cycle and apoptosis (Figure 6A ASC ( Figure 6B ), and cell-fate decisions were dependent on the particular parameter set sampled from previously determined distributions (see STAR Methods; Mitchell et al., 2018 Only cells that had increased Blimp1 expression showed decreased cRel activity, and they showed further decreases at later time points as they differentiated into ASCs ( Figure 6C ), whereas RelA activity remained similar in ABCs and ASCs ( Figure S6A ). According to parameter distributions, cells showed heterogeneity in cRel activation dynamics and the timing and generation number of ASC differentiation ( Figure 6C ). The model predicted that ASCs generated at early time points produced a higher percentage of proliferating cells than did those generated at a later time point (Figures 6D and S6B) .
To examine the time evolution of molecular markers and generate an experimentally testable prediction of the multi-scale modeling of signaling, proliferation, apoptosis, and differentiation, we tracked cRel and Blimp1 concentrations over time in a population of individually simulated cells ( Figure 6E and Video S1). The resulting plot of the cell population's path through the space of cRel and Blimp1 expression revealed a distinctive trajectory that allowed us to quantify specific populations of B cells on the basis of their cRel and Blimp1 expression ( Figure 6F ). To test this prediction, we measured Blimp1 and cRel abundance with single-cell resolution through a flow-cytometry time course and found that B cells first increased cRel expression at 24 h, and $70% of cells were considered cRel high at 24 and 48 h ( Figures 6G and 6H ). Increased cRel expression was followed by increased Blimp1 expression, such that the percentage of Blimp1 high cells increased from 20% at 24 h to 55% at 48 h and $80% at 72 and 96 h. As predicted by the model, B cells that showed increased Blimp1 subsequently reduced cRel expression, whereby the percentage of cells with both high Blimp1 and high cRel decreased from 41% at 48 hr to 29% at 72 hr and 22% at 96 hr, and the population of cells with high Blimp1 and low cRel increased from 15% at 48 hr to 53% at 72 and 96 hr. This confirmed the computational prediction that proliferation and differentiation dynamics of stimulated B cells are accompanied by first high and then decreased cRel expression after increased expression of Blimp1 at 72 and 96 h ( Figures  6G and 6H ).
Multi-scale Modeling Relates Genetic Perturbations to Physiological or Pathological B Cell Population Dynamics
To further investigate the predictive power of the multi-scale model, we examined its ability to recapitulate population dynamics of WT and Rel À/À B cells. In the WT condition ( Figure 7A, left), the model simulations showed a characteristic transient dip in the total population as a result of the death of a proportion of founder cells before proliferation results in a total population expansion that then gives way to a population decline. During the proliferative burst, some cells differentiated into ASCs, resulting in ASC population dynamics that are distinct but necessarily coordinated with the ABC population dynamics. In the Rel The multi-scale model is composed of the NFkB regulatory network (green box), the apoptosis gene regulatory network (gray box), the cell-cycle gene regulatory network (blue box) as published previously (Mitchell et al., 2018; Shokhirev et al., 2015) , and the ASC differentiation circuit (violet and red box) added here. (legend continued on next page) 2015). Although the ASC population was also diminished, their proportion of the total was substantially higher in the cRel-deficient population than in WT controls, reflecting the enhanced propensity to differentiate ( Figures 7A and 5B) . By analyzing the simulation data not as a function of time but as a function of generation at a single time point (72 h), we found that the model predicted that cRel-deficiency results in an overall increase in ASC differentiation, which in fact peaks at an earlier generation than in WT cells ( Figure 7B , left). The experimental data ( Figure 5G ) confirmed this prediction ( Figure 7B , right), though peak ASC proportions appeared one generation later in both genotypes. In sum, the multi-scale model appeared to recapitulate key aspects of ABC and ASC population dynamics and the intricate roles of cRel in shaping them. The concordance between model simulations and experimental observations encouraged us to use the multi-scale model as a research tool to explore the consequence of NFkB dysregulation on B cell population dynamics. Simulations of Blimp1 deficiency resulted in increased Rel expression ( Figure 7C ) and elevated B cell proliferation ( Figure S7 ) in line with experimental observation (Calado et al., 2010) . Simulation of elevated cRel expression resulted in a dramatic increase in the expansion of the ABC population and a reduction and delay in the generation of ASCs not only proportionally but also in absolute numbers ( Figure 7D, left) , reflecting experimental observations ( Figure 2G ). Next, we simulated the effects of disrupting the Blimp1 binding sites in the Rel locus, which did not substantially alter total ABC cell population dynamics but did result in a reduction in the generation of ASCs ( Figure 7D, middle) . This was consistent with the reduced antibody production observed experimentally ( Figure 4G ). Finally, we explored the effect of elevated RelA expression, which led to increased total cell population expansion, comparable to elevated cRel simulations. But, in contrast to the elevated cRel condition, elevated RelA produced predominantly ASCs ( Figure 7D , right). Similar misregulation of the NFkB system is associated with different B cell lymphomas originating from distinct phases of the GC reaction ( Figure 7E) . GC B-cell-like diffuse large cell lymphomas (GCB DLBCLs) are associated with high cRel expression, and similar to the cRel high simulations, GCB DLBCL cells appear trapped at the cRel high stage and unable to exit the GC (Rosenwald et al., 2002; Shaffer et al., 2002b) . Activated B-cell-like diffuse large cell lymphomas (ABC-DLBCLs) show high RelA and moderately high cRel activity with frequent Blimp1 inactivation. As seen in the Blimp1 deficiency simulation, such cells are trapped at the pre-plasmablast stage (i.e., able to initiate but unable to complete plasmacytic differentiation) (Davis et al., 2001 ). In contrast, malignant plasma cell disorder multiple myeloma (MM) is characterized by high RelA, and reflecting the highly differentiated state of cells in RelA high simulations, MM cells originate from fully differentiated plasma cells. The fact that our simulations of conditions of NFkB misregulation produced analogous in silico phenotypes of population dynamics ( Figure 7C ) suggests that the multi-scale model might be a useful research tool for relating genetic or molecular perturbations to the balance of proliferation and differentiation in health and disease.
DISCUSSION
In this work, we developed a quantitative understanding of how NFkB dimers control ASC differentiation; by iterating experimental and computational modeling work, we formulated an experimentally trained kinetic model of B cell proliferation and differentiation, which recapitulated experimentally observed phenotypes. Although cRel activation is critical for B cell activation and survival and ABC population expansion (Pohl et al., 2002; Shokhirev et al., 2015) , we found that its repression enabled differentiation of ABCs into ASCs. Ectopic expression of cRel in B cells prevented Blimp1 expression and consequently impaired ASC differentiation. Conversely, Rel À/À B cells showed increased Blimp1 expression and increased propensity for LPS-PB differentiation, but the LPS-PB population remained diminished, suggesting that the reduced antigen-specific antibody production (Grumont and Gerondakis, 2000; Heise et al., 2014; Pohl et al., 2002) associated with cRel deficiency is not due to a defect in ASC generation but rather an indirect consequence of defective B cell expansion. Thus, cRel dynamics are a key determinant of ABC and ASC population dynamics. Further, we established that Rel repression in ASCs is mediated by Blimp1. Blimp1 is known to repress cell-growth and -proliferation regulators such as Myc and cyclin E (Lin et al., 2000; Lin et al., 1997; Shaffer et al., 2002a) ; Rel repression might reinforce this regulation as Myc is a cRel target gene (Duyao et al., 1990) , which was shown to determine the proliferative capacity of ABCs (Heinzel et al., 2017) . A key characteristic of plasma cells is the slowing and cessation of the cell cycle, and ectopic expression of the cell-cycle-promoting regulator (cyclin E) inhibits ASC differentiation (Lin et al., 2000) . cRel expression also correlates with proliferative activity ( Our work points to a mutually antagonistic regulatory logic between cRel and Blimp1, where cRel inhibits Blimp1 expression via Bach2 and Blimp1 directly represses cRel expression. Mutual inhibition within regulatory networks can result in a bi-stable system, i.e., a system with two steady states (Kaplan and Glass, 2012 (Hoffmann et al., 2003) , but they have distinct, potentially antagonistic functions. We posit that the coordinated dynamic control of these two NFkB family members, and their relative activity over time, phase the GC reaction of B cell population expansion, SHM, and ASC generation for an effective immune response. Bi-stable systems might enforce differentiation decisions so that the differentiated state of the cell is maintained even when the differentiating stimulus has decayed (Wang et al., 2009) . Healthy ASC differentiation is indeed irreversible, and only a significant perturbation of regulatory networks, such as the overexpression of Bcl6, might lead to deactivation of the ASC-specific gene expression program (Fujita et al., 2004) . Although various ASC populations, such as PBs, PCs, and ASCs, from distinct niches show variable Blimp1 and cRel abundances, the mutual antagonistic regulation between Blimp1 and cRel might be conserved. Indeed, we found that as Blimp1 expression gradually increases from PBs to PCs, there is a concomitant decrease in cRel. An inverse correlation between Blimp1 and cRel expression was also observed in intestinal B cells and I-ASCs and in human pre-plasma cells exiting from the GC (Cattoretti et al., 2005) . Nevertheless, the Blimp1 transcriptional repression program might differ in other ways in distinct ASC populations; for example, I-ASCs fail to repress the Blimp1 target gene CD19 (Landsverk et al., 2017) , and ASC differentiation during Salmonella infections might involve a prolonged Blimp1 high AID high state resulting in GC-independent affinity maturation of PBs and pathological B cell responses (Di Niro et al., 2015) .
Here, we presented a mathematical model (NFkB-extended ASC model v.2), which demonstrated that the included gene regulatory interactions are sufficient to explain the differentiation kinetics and regulatory dynamics explored here. However, other in vivo or ex vivo experimental conditions might involve additional mechanisms. For example, recent results revealed a significant role for the complex of IRF8 and PU.1 in the propensity of B cells to undergo class-switch recombination (CSR) and ASC differentiation by concurrently promoting the expression of Bcl6 and Pax5 and repressing AID and Blimp1 (Carotta et al., 2014; Willis et al., 2017) . Furthermore, cytokines secreted by T helper cells are known to play important roles in controlling B cell fate in vivo. Thus, additional regulatory interactions not represented in the current model, including IL-2-mediated activation of Bcl6 (through Stat5), IL-21-mediated activation of Blimp1 (through Stat3), and IL-4-mediated activation of AID (Mé ndez and Mendoza, 2016; Moens and Tangye, 2014) , are most likely necessary to account for in vivo differentiation.
The dynamics of cRel are regulated transcriptionally and through dimerization, sequestration by IkB inhibitors Alves et al., 2014; O'Dea and Hoffmann, 2009) , and kinase activity (Shinohara et al., 2014) . This motivated us to incorporate the NFkB-extended ASC model v2 into an established multi-scale B cell model (Mitchell et al., 2018; Shokhirev et al., 2015) that explicitly articulates these regulatory mechanisms. With single-cell resolution, the model recapitulated dynamical changes in cRel and Blimp1 expression, cellular proliferation, and subsequent differentiation of a subset of cells as measured by flow cytometry. Interestingly, the model also recapitulated the progression of PBs that have substantial proliferative capacity and are generated early in the immune response into terminally differentiated PCs that are quiescent and are generated late in the immune response. Thus, the multi-scale model can recapitulate the generation of heterogeneous ASC populations; however, further sources of heterogeneity, including the splenic architecture's role in extrafollicular PB and GC-derived PC generation, most likely remain to be investigated experimentally and incorporated into mathematical representations.
The resulting multi-scale model was also capable of recapitulating and disentangling altered proliferation and differentiation phases in systems with genetic perturbations in key regulators such as cRel, RelA, and Blimp1. Thus, the model represents an in silico laboratory that might be used iteratively with wet-lab experiments for mechanistically investigating the variety of B cell lymphomas subtypes. Our multi-scale modeling work, supported by quantitative experimental data, suggests that coordinated dynamic regulation of cRel and RelA is critical for the switch from proliferative to ASC differentiation phases, and perturbations within this network are associated with B cell malignancies. Consequently, we suggest that dynamic mis-coordination of cRel and RelA might be a more useful concept than hyper-or hypo-activity of generic NFkB when addressing the mechanisms underlying B cell lymphoma or humoral response deficiencies.
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Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Mice were maintained in environmental control facilities at the University of California, Los Angeles. Mice of both sexes were littermates and were 10-14 weeks old unless otherwise indicated. The Rel À/À (protein name cRel) mice (Kö ntgen et al., 1995) previously described and wild-type mice were in C57BL/6 genetic background. Animal work was performed according to University of California, Los Angeles regulations under an approved protocol.
Cell Lines HEK293 (ATCC, CRL-1573) cells were cultured with DMEM, 10% FBS. BCL1 (ATCC, CRL-1669) were cultured with RPMI, 10% FBS, 5 mM L-glutamine, and 55 mM 2-Mercaptoethanol.
METHOD DETAILS
B cell isolation and culture Spleens were harvested from 10-12 weeks old female C57BL/6 mice and Rel À/À mice. Homogenized splenocytes were incubated with anti-CD43 magnetic beads for 15 min at 4-8 C, washed with MACS buffer (Phosphate buffer saline, (pH 7.4), 0.5% bovine serum albumin and 2 mM Ethylenediaminetetraacetic acid (pH 8)) and passed through LS column (Miltenyi Biotech). The purity of B cells was > 95% based on B220 staining as described previously (Mitchell et al., 2018) . Briefly, the enriched B cell population was stained with B220-eF450, CD3e-FITC, CD11b-FITC and Ly-6C-Alexa 488. The stained cells were gated on B220 B cells were grown in fresh media with 1% penicillin streptomycin solution, 5 mM L-glutamine, 20 mM HEPES buffer, 1mM MEM non-essential amino acid, 1 mM Sodium pyruvate, 10% FBS, and 55 mM 2-Mercaptoethanol.
Sorting of B cells subtypes by flow cytometry
Mature splenic B cells were plated in a 10 cm Petri-dish and treated with LPS (10 mg/mL) for 72 h in 10 mL media with 1x10 6 cells/mL.
Cells were harvested and resuspended in 100 mL of cold media. Nonspecific binding was blocked with Fc receptor blocker by incubating for 10 min on ice and stained with B220-eF450 and CD138-APC in a total of 200 mL of cold media for 30 min in ice. The excess antibody was removed and washed by centrifugation at 500 rcf, 4 C for 3 min, and then tubes were turned 180 and centrifugation was repeated. Cells were resuspended in media and dead cells were excluded using 7AAD. ABCs (B220 hi CD138 -) and ASCs (B220 low CD138 + ) were sorted based on expression of B220 and CD138 by flow cytometer ( Figure S2A ).
Inguinal lymph nodes were isolated from immunized mice. GC B cells were sorted at 7 days after primary immunization. Homogenized lymph nodes were incubated with Fc receptor blocker for 10 min in ice and stained with B220-eF450, CD3e-FITC, CD11b-FITC, CD11c-FITC, CD49b-FITC, FAS-APC and CD38-PE in a total of 100 mL of cold media for 30 min in ice. GC B cell were sorted Figure S2F ). ASCs were isolated from lymph nodes 7 days after a booster dose of immunization. Homogenized lymph nodes were incubated with Fc receptor blocker for 10 min in ice and stained with B220-eF450, CD3e-FITC, CD11b-FITC, CD11c-FITC, CD49b-FITC and CD138-APC in total 100 mL of cold media for 30 min in ice. ASCs were sorted using gating strategy B220 low CD138 + ( Figure S2G ).
Mouse immunization
10-12 weeks old female C57BL/6 mice were immunized with 100 mg of NP-OVA emulsified in Complete Freund Adjuvant in the foot pad, followed by an equivalent booster shot after 21 days.
Isolation and characterization of intestinal ASC
Isolation of murine lymphocytes from the small-intestinal lamina propria was performed as previously described (Couter and Surana, 2016) . Briefly, resected small-intestinal segments were washed, inverted, and the epithelial fraction was removed by incubating for 15 min at 37 C in RPMI with 5 mM DTT, 1 mM EDTA, and 2% FBS. The residual fraction was minced and digested for 30 min at 37 C in RPMI with collagenase II (1.5 mg/mL), dispase (0.5 mg/mL), and 1% FBS. Lamina propria single-cell suspensions were obtained by passing through 100 uM and 40 uM cell strainers, and resuspended in RPMI containing 2% FBS. Homogenized cells were incubated with fixable viability dye eF506 (Affymetrix Bioscience, #65-0866-18) in total 1 mL PBS for 30 min on ice and washed with PBS. Cells were then incubated with Fc receptor blocker for 10 min in ice and stained with B220-APC-Cy7, CD3e-FITC, CD11b-FITC, CD11c-FITC, CD49b-FITC, Ly-6G-FITC and CD138-PerCP Cy5.5 in total 100 mL of cold media for 30 min in ice. The gating strategy is similar to lymph node ASCs. B cells and ASCs were characterized using B220 + and B220 -CD138+ respectively.
Genetic modification of BCL1 cells
To lentivirally transduce BCL1 cells, HEK293 cells were transfected with all lentivirus constructs using lipofectamine (Invitrogen). 48 h post transfection, virus was harvested and used to infect murine BCL1 cells in the presence of polybrene (7.5 mg/mL). Lentivirally infected BCL1 cells were grown in the presence of puromycin for 3 days (Yoon and Boss, 2010) . Plasmids used: pLX-cRel, Bach2 À/À guide RNA (5 0 -CACCGGAACTTTCGTCCCCCTGCGC-3 0 and 5 0 -CACCGTGCTGCAGGGACGGGCACAA-3 0 ) and Blimp1 À/À guide RNA (5 0 -CACCGGAATCCAGCTCACTCTGCCC-3 0 and 5 0 -CACCGACCTGGCTGCCTGTCAGAAC À3 0 ) cloned in the LentiV2 plasmid. The efficiency of knock in and knock out was assessed by immunoblot as indicated.
Electroporation of BCL1 cells was performed as described previously (Lin et al., 2000; Lin et al., 1997) with some modifications. Briefly, 2 x10 5 cells were plated and washed with PBS (without Ca2 + and Mg2 + ). Cells were resuspended in Resuspension Buffer R at 2x10 5 cells/10 mL and 1 mg of plasmid DNA was added. Cells were gently pipetted to obtain a single cell suspension. Cells were electroporated in Neon Transfection systems (Invitrogen) and plated in 6 well plates. A pulse voltage of 1000 mW and width of 40 ms was used for electroporation. Electroporated cells were grown in the presence of puromycin for 3 days. Blimp1 binding site disruption (Rel
BBS
) was performed using guide RNA (5 0 -CACCGTACTAGAGCATCTGAAAGCC-3 0 ) cloned in the Lentiv2 plasmid. The efficiency of mutation was measured by Next Generation Sequencing. The targeted genomic region was PCR amplified (using the primer: ACTTAAAGCCTTTTTGTGCTTCT and CAGTTTCCTTTACAGCAGGAGTT) and PCR products were gel purified. The purified PCR products were submitted for amplicon-EZ (150-500 bp) sequencing (Genewiz). Adaptor-trimmed sequencing results were processed for quality control using FASTX-Toolkit. A Python script was then used to analyze counts of unique mutated or wild-type amplicons (code is available as Supplemental File 1). Piechart was plotted with Graphpad Prism (Figure S4C ).
RNA and Immunoblot Analysis
For qPCR, mRNA was isolated from B cells, ABCs, ASCs, 10 mg/mL LPS-stimulated wild-type and Rel À/À B cells following 24, 36, 38, 60 and 72 hours of culture and BCL1 cells following stimulation with IL-2 (20 ng/mL) and IL-5 (20 ng/mL), using the Zymo Research kit. 1 mg mRNA was used to prepare cDNA using Oligo (dT) and quantitation was performed using the SSO syber green. Expression was normalized using ubiquitin C as a housekeeping gene. The primers used in this study are specified in Table S3 . For Immunoblot analysis, whole-cell lysates were prepared using RIPA lysis buffer. The resulting lysates were run on either 10% SDS-PAGE gels or 5%-14% Criterion Tris-HCl Gel (Bio-Rad). The following antibodies were used to identify the protein of interest: Rela, cRel, Blimp1, IRF4, Bach2 and actin (all from Santa Cruz Biotechnology). The resulting proteins were detected using the BioRad ChemiDoc XRS System and SuperSignal West Femto Substrate Maximum Sensitivity Substrate (Thermo Scientific) to detect chemiluminescence released by HRP-labeled secondary antibodies.
IgM production measurement by ELISA For ELISA analysis, BCL1 and genetically modified BCL1 cells were plated in a 48 well plate with 2x10 5 cells/well in a 250 ml volume.
The cells were stimulated with IL-2 (20 ng/mL) and IL-5 (20 ng/mL) for 96 hr and the supernatant was collected. The resulting supernatant was tested to measure secreted IgM by ELISA. ELISA was performed using mouse Ig isotyping ELISA kit according to manufacturer protocol.
Chromatin Immunoprecipitation (ChIP)
For ChIP experiments 10x10 6 cells were washed with 10 mL PBS at room temperature (RT) and fixed with freshly supplemented 1% methanol-free formaldehyde and incubated at RT for 10-15 min with gentle shaking. The fixation reaction was quenched with 500 mM Tris pH 8 for 2-5 min. The cells were washed twice with cold PBS followed by snap freezing with dry ice. The cell pellets were thawed and resuspended on ice in 1 mL Lysis Buffer 1 and incubated on a nutator at 4 C for 10 min before centrifugation at 800 rcf, 5 min, 4 C; supernatant was then discarded. Similar steps were performed with 1 mL Lysis Buffer 2. The nuclei were resuspended in 0.5 mL Lysis Buffer 3 Plus and incubated on ice for 10 min. The lysates were transferred into 1.5 mL TPX tubes (Diagenode #C30010010-1000, min 100 ml-max 300 ml/tube) and sonicated with a Bioruptor water bath sonicator using 25 cycles consisting of 30 s ON/30 s OFF at low intensity, 4 C. Sonication was stopped every 5 cycles for incubation on ice for 1 min, gentle inversion and pulse-spin. Aliquots were consolidated with the same sample into a single 1.5 mL polypropelene tube. The lysate was centrifuged at max speed for 15 min at 4 C. The supernatants were transferred to 1.5 mL no-stick microtubes (Phenix Research #MH-815S) and 3 volumes of dilution buffer were added to lysates. Unconjugated beads (25 ml/mL of diluted lysate) were washed (twice with PBS and dilution buffer) and dried up in no-stick tubes using a magnet. Lysates were mixed with dry beads and incubated for 2 hr at 4 C on a nutator. Lysates were used for the next step and beads were discarded. 1% aliquots were taken as input and stored at 4 C with volumes noted. 2 mg anti-H3K9ac antibody and isotype IgG were incubated with the lysate overnight at 4 C on a nutator. 25 ml protein G-conjugated magnetic beads (Active Motif #53014) were washed twice with Dilution Buffer, then once with low-salt buffer. Beads were dried using a magnetic rack. Lysates were transferred to dry beads and incubated for 5 hr at 4 C on a nutator. Beads were collected using a magnetic stand and washed twice with each of the following ice-cold buffers in order: low salt, high salt, LiCl, TE. 600 ml of buffer was used in each wash step and beads were resuspended by inversion, and placed in a high-speed shaker at RT for 5 min. Beads were resuspended in 70 ml of 250 mM NaCl. Input fractions were recovered and volumes were adjusted to 70 ml with 250 mM final concentration of NaCl. Both input and IP fractions were processed in a similar way after this. 50 mg DNase-free RNase A (Roche #11119915001) was added and incubated at 37 C for 1 hr with gentle mixing. SDS was added for a 1% final concentration and then 50 mg Proteinase K (Roche # 03115828001) was added for an overnight incubation at 60 C with gentle shaking. SPRI beads were resuspended by gentle vortexing, allowed to warm to RT and the supernatant was removed from Protein G beads. Protein G beads were washed with an additional 30 ml of 500 mM NaCl and combined with the first eluate. 0.9-1.0 volumes of SPRI beads were added and incubated at RT for 15 min on a nutator. Beads were collected using a magnetic stand and supernatants were removed. Beads were twice washed with 80% ethanol and residual ethanol from tubes was removed by air-drying beads for 5 min. DNA was eluted from beads with 30 ml TE buffer. Enrichment of the targeted DNA in the elution was measured by qPCR and the enrichment was calculated with respect to input. Buffer composition Lysis Buffer 1: 50 mM HEPES-KOH, pH 7.6, 140 mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% NP-40, 0.25% Triton X-100, EDTA-free protease inhibitors.
Lysis Buffer 2: 10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, EDTA-free protease inhibitors. Lysis Buffer 3: 10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na Deoxycholate, 0.5% N-lauroylsarcosine, sodium salt (Sigma-Aldrich #61739), EDTA-free protease inhibitors.
Dilution Buffer: 10 mM Tris-HCl, pH 8.0, 160 mM NaCl, 1 mM EDTA, 0.01% SDS, 1.2% Triton X-100, EDTA-free protease inhibitors. Low Salt Wash Buffer: 50 mM HEPES-KOH, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na Deoxycholate, 0.1% SDS, EDTA-free protease inhibitors.
High Salt Wash Buffer: 50 mM HEPES-KOH, pH 7.6, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na Deoxycholate, 0.1% SDS.
LiCl Buffer: 20 mM Tris-HCl, pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% Na Deoxycholate, 0.5% NP-40. TE Buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA)
Measurement of apoptotic cells in ABC and LPS-PB WT and Rel À/À B cells were treated with LPS (10 mg/mL) for 72 h as described above. Cells were harvested and resuspended in 100 mL of cold media. Nonspecific binding was blocked with Fc receptor blocker by incubating for 10 min on ice and stained with B220-PE and CD138-APC in a total of 200 mL of cold media for 30 min in ice. Stained cells were washed with FACS buffer (PBS with 5% FBS) and resuspended in Annexin V binding buffer. The staining of Annexin V Alexa Fluor 488 and Propidium Iodide (PI) was performed using Dead Cell Apoptosis Kit (ThermoFisher Scientific, # V13241) as described by manufacturer protocol. Briefly, 5 mL Alexa Fluor 488 annexin V and 1 mL PI (100 mg/mL PI working solution) were added to 100 mL of cell suspension. The cells were incubated at room temperature for 15 min. 400 mL annexin-binding buffer was added, mixed gently, and the samples were acquired in BD LSRFortessa flow cytometry (BD Bioscience). Data were analyzed with FlowJo. The gating strategy and ABC and LPS-PBs were characterized by as described above. ABC and LPS-PBs population were gated for Annexin V and PI positivity. The apoptotic cells were defined as AnnexinV + PI -( Figure S5C ).
Measurement of generation-specific ASC
WT and Rel À/À B cells stained with Cell Trace Far Red (CTR) using CellTrace Far Red Cell Proliferation Kit (ThermoFisher Scientific, # C34564) as described by the manufacturer protocol. Briefly, cells were resuspended in 1 mL RT PBS and incubated with 1 mL CTR for 25 min at RT with rotation. Cells were washed followed by resuspension in RPMI with 10% FBS and incubated for 10 min at RT. The cells were washed and washing steps were repeated 1 more time. CTR labeled cells were treated with LPS (10 mg/mL) for 24 h, 48 h, 72 h and 96 h as described above. The cells were harvested at indicated time points, stained for CD138 and 7AAD as described above. 
Intracellular staining
Naive mature B cells (B cells) were isolated from spleens as described above. Cells were treated with LPS (10 mg/mL) in 12 well plates (5x10 5 /well) for 0, 24, 48, 72 and 96 hours. Cells were washed twice with PBS, followed by permeabilization and staining with primary antibody and then secondary antibody using Fix and Perm cell permeabilization kit (ThermoFisher, # GAS003). Cell permeabilization and staining protocol as described by the manufacturer was followed. Cells were stained with cRel-PE and Blimp1-Alexa 647 antibody to measure expression of cRel and Blimp1 respectively by flowcytometry. B cells were treated with anti-CD40 antibody (10 mg/mL) and IL-4 (5 ng/mL) for 72 h and stained for ABCs and CD40-PB as described above. Intracellular expression of cRel and Rela was measured using cRel-eF660 and Rela-PE respectively by flowcytometry using CytoFlex flow cytometry (488nm 50mW laser) (Beckman Coulter) and data were analyzed with FlowJo.
Intestinal lymphocytes were isolated and characterized as described above. Intracellular expression of cRel and Blimp1 was measured using cRel-PE and Blimp1-Alexa 647 respectively by BD LSRFortessa flow cytometry (BD Bioscience) and data were analyzed with FlowJo. C and turned the tube 180 to repeat centrifugation. Cells were treated with 50 ml of a 100 mg/mL sock of RNase A for 15 min at 37 C and 200 ml of propidium iodide (PI) from 50 mg/mL stock solution were incubated for 15 min at RT.
Cell Cycle Analysis
The cells were acquired in flow cytometer (CytoFLEX, Beckman Coulter). The cells were gated based on forward scattered (FSC) and side scattered to identify single cells. Doublet were excluded from analysis using FSC area and FSC width. The DNA content was measured by staining with PI.
Computational Modeling of the ABC-ASC Differentiation Circuit
Computational modeling was performed in MATLAB by re-constructing the system of ODEs, with identical parameters and reactions as described by Sciammas et al. (2011) . ODE solver ODE45 was used throughout. To construct the NFkB-extended ASC model v1, cRel and RelA were included with two additional differential equations. Additional reactions were included as shown in Figures 1B  and 3A with similar kinetic rate laws. Briefly, degradation was mass action with Hill equations used for activation and inhibition. Parameters and thresholds were chosen to be consistent with Sciammas et al. and maintained the same throughout (Sciammas et al., 2011) . All equations, parameters and initial conditions are given in Data S1, Tables S1 and S2. While the previously published model sampled IRF4 activation rates to simulate cell-to-cell variability of activation strength, here we sampled cRel and Rela activation rates with the same coefficient of variation (0.4) as used for IRF4 in Sciammas et al. cRel downregulation (Figure 1 ) was investigated by running a time course simulation of 125 individual cells for 96 hours then taking the final molecular abundances as an initial condition of a subsequent 96 hour simulation in which cRel expression was reduced as indicated.
To construct the NFkB-extended ASC model v2, Blimp1-mediated cRel downregulation was incorporated through hill kinetics consisted with the NFkB-extended ASC model model v1. Constant cRel expression ðe c = 1Þ was replaced with: To simulate Rel À/À we set cRel expression to 0 and simulated a population of 125 individual cells. ASC generation in cRel deficiency is controlled by RelA, RT-PCR analysis showed that Rel À/À B cells reduced RelA expression at 24 h (20%-40%) and had very similar expression at 72 h compared to wild-type. This was incorporated into our Rel À/À simulations through reducing RelA expression rate (40% of WT) up to 24h and returning this rate to near WT (70% of WT) for the remaining simulation time.
Multiscale Modeling
The NFkB-extended ASC model v2 constructed here was combined with a published model of B cell proliferation (Mitchell et al., 2018) to create a multiscale model capable of simulating the division, death and differentiation of a population of individual cells. All reactions and parameters within the differentiation circuit were maintained as described here and all reactions and parameters within the NFkB, apoptosis and mitosis networks were maintained as described by Mitchell et al. (Mitchell et al., 2018) . NFkB activation sampling as described above for NFkB-extended ASC model v1 and v2 was not performed here as cell-to-cell variability was quantified in Mitchell et al. and simulated here in the same manner resulting in realistically distributed NFkB activities. As the absolute concentration of cRel in the differentiation model and multiscale model differed (due to the arbitrary concentrations of molecular species in the previously published differentiation model (Sciammas et al., 2011) ) the K D of cRel-and Rela-mediated reactions in the differentiation circuit were scaled to be approximately half the maximum cRel and Rela concentrations observed in simulations from Mitchell et al. A population of 1000 single cells was simulated and scatterplots of cRel versus Blimp1 were created every 15 min for 124 hours (Video S1 and Figure 6E ). Rel À/À simulations were performed by removing cRel expression and reducing RelA expression as described for the ASC differentiation model. A similar approach was taken to Blimp1, with Blimp1 À/À simulated by scaling Blimp1 expression by 50%. Rel BS-seq cells were simulated by removing terms representing Blimp1 inhibition of cRel expression from the ODE for cRel. cRel-High simulations were performed by increasing cRel expression 5-fold. All code is available at http:// www.signalingsystems.ucla.edu/models-and-code/.
QUANTIFICATION AND STATISTICAL ANALYSIS
Details of the statistical tests applied to replicates of datasets shown in Figures can be found in the corresponding Figure legends . Statistical analyses were performed using GraphPad Prism 7 software. *p < 0.05, **p < 0.01, ***p < 0.001 and not significant (ns) (Unpaired Students t test).
DATA AND SOFTWARE AVAILABILITY
Equations of the mathematical model of the ABC-ASC differentiation circuit are provided in Data S1. MATLAB code for all models is available at http://www.signalingsystems.ucla.edu/models-and-code/. The analysis tool of CRISPR mutation efficiency is available as python code as Data S2.
